Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinicgrid.66875.3a, Rochester, Minnesota, USA.
Department of Medicine, Division of Infectious Diseases, Mayo Clinicgrid.66875.3a, Rochester, Minnesota, USA.
Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0243221. doi: 10.1128/aac.02432-21. Epub 2022 Mar 21.
The epidemiology of macrolide resistance in () in the United States is incompletely described. Using a PCR assay targeting common mutations associated with macrolide resistance in M. pneumoniae (23S rRNA gene, A2063G/A2064G), the frequency of macrolide resistance was estimated to be 10% based on analysis of 114 samples tested from January 2014 to September 2021 at Mayo Clinic Laboratories. Seasonality data showed the highest rates of M. pneumoniae infection in the fall/early winter.
在美国,()中大环内酯类耐药的流行病学情况描述并不完整。本研究采用针对肺炎支原体中常见大环内酯类耐药相关突变(23S rRNA 基因,A2063G/A2064G)的 PCR 检测方法,对 2014 年 1 月至 2021 年 9 月在 Mayo 诊所实验室检测的 114 份样本进行分析,估计大环内酯类耐药的频率为 10%。季节性数据显示,肺炎支原体感染的高发期在秋季/初冬。